Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
Intrinsic Value
Shenzhen Kangtai Biological Products Co., Ltd. engages in the manufacture, sale, and research and development of human vaccines. [ Read More ]
The intrinsic value of one
Shenzhen Kangtai Biological Products Co Ltd
stock under the Base Case scenario is
28.24
CNY.
Compared to the current market price of 20.75 CNY,
Shenzhen Kangtai Biological Products Co Ltd
is
Undervalued by 27%.
Shenzhen Kangtai Biological Products Co Ltd's market capitalization is 23.2B CNY.
Shenzhen Kangtai Biological Products Co Ltd stock price is 20.75 CNY.
Shenzhen Kangtai Biological Products Co Ltd stock price (20.75 CNY) is 27% less than its Intrinsic Value (28.24 CNY).
Shenzhen Kangtai Biological Products Co Ltd stock (16.13 CNY) is 22% less than its price (20.75 CNY). Open DCF Valuation
Shenzhen Kangtai Biological Products Co Ltd stock price (20.75 CNY) is 49% less than its Relative Value (40.35 CNY). Open Relative Valuation
Shenzhen Kangtai Biological Products Co Ltd has upside potential of 82% compared to the average analyst price target.
Open Wall St Estimates
Shenzhen Kangtai Biological Products Co Ltd has positive three-year average ROE (Return on Equity): 9%. The company is efficient at transforming stockholders' equity into net income.
Shenzhen Kangtai Biological Products Co Ltd has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
Shenzhen Kangtai Biological Products Co Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 4%.
Shenzhen Kangtai Biological Products Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
Shenzhen Kangtai Biological Products Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 12% to 3%.
Shenzhen Kangtai Biological Products Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 14% to 4%.
Shenzhen Kangtai Biological Products Co Ltd has positive Net Income for the last twelve months.
Shenzhen Kangtai Biological Products Co Ltd has positive Net Debt. This means that the company has more debt (3B CNY) than cash and short-term investments (1B CNY).
Shenzhen Kangtai Biological Products Co Ltd has positive Operating Income for the last twelve months.
Shenzhen Kangtai Biological Products Co Ltd's Revenue has been growing by 16% per year for the last 3 years.
Shenzhen Kangtai Biological Products Co Ltd's Revenue has dropped by 20% over the past 12 months.
Shenzhen Kangtai Biological Products Co Ltd's Revenue is forecast to grow at a rate of 25% per year over the next 3 years.
Shenzhen Kangtai Biological Products Co Ltd's short-term assets (5B CNY) exceed its short-term liabilties (3B CNY).
Shenzhen Kangtai Biological Products Co Ltd has positive Gross Profit for the last twelve months.
Shenzhen Kangtai Biological Products Co Ltd's long-term assets (15B CNY) exceed its long-term liabilties (5B CNY).
Shenzhen Kangtai Biological Products Co Ltd has positive Free Cash Flow for the last twelve months.
Shenzhen Kangtai Biological Products Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.26.
Shenzhen Kangtai Biological Products Co Ltd's Altman Z-Score is very high and is equal to 4.5.
Valuation Backtest
Shenzhen Kangtai Biological Products Co Ltd
Run backtest to discover the historical profit from buying and selling
Shenzhen Kangtai Biological Products Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Shenzhen Kangtai Biological Products Co Ltd
Balance Sheet Decomposition
Shenzhen Kangtai Biological Products Co Ltd
| Current Assets | 5.4B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 2.7B |
| Other Current Assets | 1.7B |
| Non-Current Assets | 9.3B |
| Long-Term Investments | 49.2k |
| PP&E | 5.8B |
| Intangibles | 501m |
| Other Non-Current Assets | 3B |
| Current Liabilities | 2.5B |
| Accounts Payable | 641.5m |
| Accrued Liabilities | 28.3m |
| Short-Term Debt | 277.6m |
| Other Current Liabilities | 1.6B |
| Non-Current Liabilities | 2.6B |
| Long-Term Debt | 2.2B |
| Other Non-Current Liabilities | 385.5m |
Earnings Waterfall
Shenzhen Kangtai Biological Products Co Ltd
|
Revenue
|
3.1B
CNY
|
|
Cost of Revenue
|
-531m
CNY
|
|
Gross Profit
|
2.5B
CNY
|
|
Operating Expenses
|
-2.2B
CNY
|
|
Operating Income
|
292.2m
CNY
|
|
Other Expenses
|
69m
CNY
|
|
Net Income
|
361.2m
CNY
|
Free Cash Flow Analysis
Shenzhen Kangtai Biological Products Co Ltd
Profitability Score
Profitability Due Diligence
Shenzhen Kangtai Biological Products Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Shenzhen Kangtai Biological Products Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shenzhen Kangtai Biological Products Co Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Shenzhen Kangtai Biological Products Co Ltd's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shenzhen Kangtai Biological Products Co Ltd
According to Wall Street analysts, the average 1-year price target for
Shenzhen Kangtai Biological Products Co Ltd
is 37.68 CNY
with a low forecast of 33.22 CNY and a high forecast of 48.3 CNY.
Shareholder Return
Price
Shenzhen Kangtai Biological Products Co Ltd
| Average Annual Return | 17.21% |
| Standard Deviation of Annual Returns | 71.11% |
| Max Drawdown | -87% |
| Market Capitalization | 23.2B CNY |
| Shares Outstanding | 1 116 909 952 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Shenzhen Kangtai Biological Products Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Shenzhen Kangtai Biological Products Co., Ltd. engages in the manufacture, sale, and research and development of human vaccines. The company is headquartered in Shenzhen, Guangdong and currently employs 2,445 full-time employees. The company went IPO on 2017-02-07. is a China-based company and mainly engaged in research and development, manufacture and sale of vaccine. The main products of the company are recombinant hepatitis B virus, haemophilus influenzae type b combined vaccine, measles rubella combined attenuated live vaccine, non-cell Bai Bai Po haemophilus influenzae combined vaccine and other products. The firm operates its businesses primary in domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
Shenzhen Kangtai Biological Products Co Ltd
stock under the Base Case scenario is
28.24
CNY.
Compared to the current market price of 20.75 CNY,
Shenzhen Kangtai Biological Products Co Ltd
is
Undervalued by 27%.
You don't have any saved screeners yet
